The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hologic's revenues will increase 33.3% and EPS will grow 5.7%.
The average estimate for revenue is $626.9 million. On the bottom line, the average EPS estimate is $0.37.
Last quarter, Hologic booked revenue of $612.7 million. GAAP reported sales were 30% higher than the prior-year quarter's $471.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $0.35. GAAP EPS were -$0.19 for Q2 versus -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 61.6%, 40 basis points better than the prior-year quarter. Operating margin was 11.5%, 500 basis points worse than the prior-year quarter. Net margin was -8.3%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.54 billion. The average EPS estimate is $1.54.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 670 members out of 690 rating the stock outperform, and 20 members rating it underperform. Among 161 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 154 give Hologic a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $25.24.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.